Gilead Sciences, Inc. (SNSE:GILDCL)
Chile · Delayed Price · Currency is CLP | Market Cap | 166.34T +16.8% |
| Revenue (ttm) | 28.06T +5.5% |
| Net Income | -2,985.01B |
| EPS | -2,409.19 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.01 |
| Dividend | 2,958.34 (2.33%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 127,000 |
| Day's Range | n/a |
| 52-Week Range | 79,000 - 128,950 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to ...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europ...
AHF Crowns Gilead Corporate Welfare King
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Gilead Sciences Earnings Call Transcript: Q2 2026
Base business sales grew 10% year-over-year, led by HIV, oncology, and liver disease. HIV sales rose 12%, with PrEP sales doubling and exceeding $1 billion quarterly. Raised full-year guidance for HIV and total product sales, while integrating major acquisitions and preparing for key product launches.
Gilead Sciences Earnings release: Q2 2026
Gilead Sciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q2 2026
Gilead Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Gilead Sciences Quarterly report: Q2 2026
Gilead Sciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Gilead second-quarter sales rise 8%, beating Wall Street estimates
Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of acquisitions...
Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second qua...
California's highest court rules for Gilead, says drugmakers don't have 'duty to innovate'
California's highest court ruled on Monday that manufacturers of drugs that are considered safe do not owe a duty to patients to try developing drugs that could be even safer, ruling in favor of Gil...
California's highest court rules for Gilead in 'duty to innovate' case
California's highest court on Monday ruled in favor of Gilead Sciences , in a case addressing whether manufacturers of drugs that are considered safe must try developing drugs that could be safer.
CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ado...
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4...
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first re...
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janei...
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed...
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure trea...
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first...
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.
AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo...